Hevolution Foundation
VC Fund
Riyadh, Saudi Arabia
Hevolution Foundation is a VC fund in Riyadh focused on Biotechnology and Health Care. Hevolution is a research, science, and expertise in the field of healthspan science, reshaping policy, and regulation to support healthspan science for everyone's benefit. It offers humanity a path to a health span by supporting innovation in life sciences and medicine that focuses on the biology of aging itself rather than disease.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Hevolution Foundation invests in
Stages Hevolution Foundation invests in
Countries Hevolution Foundation invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mehmood Khan
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 3 (33%)
- Health Care 2 (22%)
- Pharmaceutical 2 (22%)
- Biopharma 1 (11%)
- Manufacturing 1 (11%)
Stage
- Series A 3 (33%)
- Series B 2 (22%)
- Grant 1 (11%)
Country
- United States 3 (33%)
- Switzerland 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mehmood Khan
Chief Executive Officer
|
Chief Executive Officer | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M / Series B / Dec 16, 2025 | |
Tune Therapeutics
|
Tune Therapeutics strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases. | $175M / Series B / Jan 12, 2025 | |
|
Tune Therapeutics
|
Tune Therapeutics strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases. | $175M / Series B / Jan 12, 2025 | |
Vandria
|
Vandria creates mitophagy inducers that renew cells in order to address aging and chronic disorders. | $10.1M / Series A / Aug 21, 2024 | |
Rubedo Life Sciences
|
Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. | $40M / Series A / Apr 22, 2024 | |
|
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $50M / Series A / Mar 28, 2024 | |
|
Aeovian Pharmaceuticals
|
Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $50M / Series A / Mar 28, 2024 | |
American Federation for Aging Research
|
American Federation for Aging Research is an advance & support healthy aging through biomedical research. | $16M / Grant / Dec 01, 2023 | |
Impetus Grants
|
Impetus Grants provide funds for scientists to immediately begin working on the most important topics in aging biology. | Grant |
Co-Investors
Apollo Health Ventures
3 deals together
Sofinnova Investments
3 deals together
venBio Partners
3 deals together
b2venture
2 deals together
Evotec
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hevolution Foundation invest in?
Hevolution Foundation invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hevolution Foundation?
Public channels for Hevolution Foundation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hevolution Foundation?
The team at Hevolution Foundation includes Mehmood Khan (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
